RT Journal
A1 Stephenson J
T1 Study halted: No benefit seen from antiretroviral pill in preventing hiv in women
JF JAMA
JO JAMA
YR 2011
FD May 18
VO 305
IS 19
SP 1952
OP 1952
DO 10.1001/jama.2011.649
UL http://dx.doi.org/10.1001/jama.2011.649
AB 
The study, called FEM-PrEP, is a randomized clinical trial of the safety and effectiveness of a daily pill containing emtricitabine and tenofovir (a combination sold under the name Truvada) in preventing HIV infection in women in Africa who are at higher risk of being exposed to HIV. It is one of several trials testing the use of antiretroviral drugs as a prevention strategy in at-risk populations.